• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关键时机:手术延迟对Ⅰ-Ⅱ期非小细胞肺癌预后的影响

Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.

作者信息

Zhang Ye, Hu Yeji, Xi Jinfeng, Wu Bo, Zhang Wenxiong, Li Chunling

机构信息

Department of Thoracic Surgery, iangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

Department of Thoracic Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

出版信息

PLoS One. 2025 May 28;20(5):e0319357. doi: 10.1371/journal.pone.0319357. eCollection 2025.

DOI:10.1371/journal.pone.0319357
PMID:40435345
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12118990/
Abstract

BACKGROUND

Delaying surgery affects the prognosis of patients with lung cancer, but the critical time point at which it becomes detrimental to survival. Identifying this critical time point may benefit patients and guide clinical practice.

METHODS

Data from patients diagnosed with stage I-II non-small cell lung cancer (NSCLC) were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression analyses were employed to evaluate prognostic factors associated with overall survival (OS) and to identify time points from diagnosis to surgery that significantly impact prognosis. Kaplan-Meier curves and subgroup analyses were conducted to validate the affect of early versus late surgery on OS. Multinomial logistic regression was utilized to evaluate factors associated with delays in the time from diagnosis to surgery.

RESULTS

We included 55,582 adult patients with stage I-II NSCLC from the SEER database. Time to surgery (TTS) was identified as an independent prognostic factor for OS in stage I-II NSCLC patients through multivariate Cox regression analysis. Compared to surgeries performed within 6 weeks of TTS, those performed after 6 weeks of TTS (HR: 1.22, 95% CI: 1.20-1.25, P < 0.001) were significantly related to poorer OS. Multinomial logistic regression revealed that age, sex, race, and marital status were risk factors for delayed TTS after diagnosis. Compared to patients with a TTS of 0-40 days, those with a TTS of 63-111 days had the following risks: for patients aged ≥ 75 years, the odds ratio (OR) was 1.46 (95% CI: 1.32-1.62, P < 0.001); for males, the OR was 1.15 (95% CI: 1.09-1.20, P < 0.001).

CONCLUSION

Compared to stage I-II NSCLC patients who underwent surgery more than 6 weeks after diagnosis, those who underwent surgery within 6 weeks had significantly higher survival rates. Delays in surgery were associated with adverse social factors.

摘要

背景

手术延迟会影响肺癌患者的预后,但对于生存产生不利影响的关键时间点尚不清楚。确定这一关键时间点可能会使患者受益并指导临床实践。

方法

从监测、流行病学和最终结果(SEER)数据库中提取诊断为I-II期非小细胞肺癌(NSCLC)患者的数据。采用单因素和多因素Cox回归分析评估与总生存期(OS)相关的预后因素,并确定从诊断到手术的时间点对预后有显著影响。进行Kaplan-Meier曲线和亚组分析以验证早期手术与晚期手术对OS的影响。利用多项逻辑回归评估与从诊断到手术时间延迟相关的因素。

结果

我们纳入了SEER数据库中的55582例I-II期NSCLC成年患者。通过多因素Cox回归分析,手术时间(TTS)被确定为I-II期NSCLC患者OS的独立预后因素。与在TTS 6周内进行的手术相比,在TTS 6周后进行的手术(HR:1.22,95%CI:1.20-1.25,P<0.001)与较差的OS显著相关。多项逻辑回归显示,年龄、性别、种族和婚姻状况是诊断后TTS延迟的危险因素。与TTS为0-40天的患者相比,TTS为63-111天的患者有以下风险:对于年龄≥75岁的患者,比值比(OR)为1.46(95%CI:1.32-1.62,P<0.001);对于男性,OR为1.15(95%CI:1.09-1.20,P<0.001)。

结论

与诊断后6周以上接受手术的I-II期NSCLC患者相比,6周内接受手术的患者生存率显著更高。手术延迟与不良社会因素有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/08c109753537/pone.0319357.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/2213a076f7a4/pone.0319357.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/828e56308f30/pone.0319357.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/eda0e00ede29/pone.0319357.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/08c109753537/pone.0319357.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/2213a076f7a4/pone.0319357.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/828e56308f30/pone.0319357.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/eda0e00ede29/pone.0319357.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/221a/12118990/08c109753537/pone.0319357.g004.jpg

相似文献

1
Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.关键时机:手术延迟对Ⅰ-Ⅱ期非小细胞肺癌预后的影响
PLoS One. 2025 May 28;20(5):e0319357. doi: 10.1371/journal.pone.0319357. eCollection 2025.
2
Analysis of Delayed Surgical Treatment and Oncologic Outcomes in Clinical Stage I Non-Small Cell Lung Cancer.临床Ⅰ期非小细胞肺癌延迟手术治疗与肿瘤学结局分析。
JAMA Netw Open. 2021 May 3;4(5):e2111613. doi: 10.1001/jamanetworkopen.2021.11613.
3
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
4
Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.用于经手术或根治性放疗治疗的Ⅰ至Ⅲ期非小细胞肺癌的免疫疗法(不包括检查点抑制剂)。
Cochrane Database Syst Rev. 2017 Dec 16;12(12):CD011300. doi: 10.1002/14651858.CD011300.pub2.
5
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
6
Survival benefit of postoperative chemotherapy in stage III lung squamous cell carcinoma based on SEER database analysis through propensity score matching.基于监测、流行病学和最终结果(SEER)数据库分析及倾向评分匹配的Ⅲ期肺鳞状细胞癌术后化疗的生存获益
Sci Rep. 2025 Jul 1;15(1):22210. doi: 10.1038/s41598-025-07766-0.
7
Comprehensive study of clinical features, prognostic factors, and survival in patients with pancreatic solid pseudopapillary neoplasms based on the 2019 WHO classification.基于 2019 年 WHO 分类的胰腺实性假乳头状瘤患者临床特征、预后因素和生存的综合研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12393-12404. doi: 10.1007/s00432-023-04982-x. Epub 2023 Jul 13.
8
Lymph node ratio emerges as a pivotal prognostic determinant for cancer-specific survival amidst individuals diagnosed with stage N1 and N2 non-small cell lung carcinoma: A population-based retrospective cohort study.在被诊断为N1和N2期非小细胞肺癌的个体中,淋巴结比率成为癌症特异性生存的关键预后决定因素:一项基于人群的回顾性队列研究。
Medicine (Baltimore). 2025 Apr 18;104(16):e42202. doi: 10.1097/MD.0000000000042202.
9
Postoperative radiotherapy enhances survival in NSCLC patients with moderate lymph node metastases following surgery: A SEER-based population cohort study.术后放疗可提高非小细胞肺癌术后中度淋巴结转移患者的生存率:一项基于监测、流行病学和最终结果(SEER)数据库的人群队列研究。
Medicine (Baltimore). 2025 Jul 25;104(30):e43367. doi: 10.1097/MD.0000000000043367.
10
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.辅助性表皮生长因子受体(EGFR)酪氨酸激酶抑制剂(TKIs)用于治疗已切除的Ⅰ至Ⅲ期非小细胞肺癌且伴有EGFR突变的患者。
Cochrane Database Syst Rev. 2025 May 27;5(5):CD015140. doi: 10.1002/14651858.CD015140.pub2.

引用本文的文献

1
Correction: Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.更正:关键时机:手术延迟对Ⅰ-Ⅱ期非小细胞肺癌预后的影响
PLoS One. 2025 Aug 20;20(8):e0330646. doi: 10.1371/journal.pone.0330646. eCollection 2025.
2
Correction: Critical timing: Impact of delays to surgery on prognosis in stage I-II non-small cell lung cancer.更正:关键时机:手术延迟对Ⅰ-Ⅱ期非小细胞肺癌预后的影响
PLoS One. 2025 Jul 22;20(7):e0328912. doi: 10.1371/journal.pone.0328912. eCollection 2025.

本文引用的文献

1
Can We Offset Local Recurrence in Locally Advanced Non-Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes.局部晚期非小细胞肺癌的局部复发能否得到控制?放疗剂量递增和顽固结局的循环往复。
J Clin Oncol. 2024 Nov 20;42(33):3895-3900. doi: 10.1200/JCO-24-01448. Epub 2024 Oct 4.
2
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
3
Recurrence-Free Survival in Patients With Surgically Resected Non-Small Cell Lung Cancer: A Systematic Literature Review and Meta-Analysis.
手术切除的非小细胞肺癌患者的无复发生存:系统文献回顾和荟萃分析。
Chest. 2024 May;165(5):1260-1270. doi: 10.1016/j.chest.2023.11.042. Epub 2023 Dec 6.
4
Reexamining Time From Breast Cancer Diagnosis to Primary Breast Surgery.重新审视从乳腺癌诊断到原发性乳房手术的时间。
JAMA Surg. 2023 May 1;158(5):485-492. doi: 10.1001/jamasurg.2022.8388.
5
Association of Pretreatment Physical and Geriatric Parameters with Treatment Tolerance and Survival in Elderly Patients with Stage I-II Non-Small Cell Lung Cancer: An Evaluation of Usual Care Data.老年Ⅰ-Ⅱ期非小细胞肺癌患者预处理身体和老年医学参数与治疗耐受性及生存的相关性:常规护理数据评估
Cancers (Basel). 2022 Dec 5;14(23):5994. doi: 10.3390/cancers14235994.
6
Survival effects of time to surgery for Stage I lung cancer: A population-based study.Ⅰ期肺癌手术时机的生存效果:一项基于人群的研究。
Surg Oncol. 2022 Jun;42:101744. doi: 10.1016/j.suronc.2022.101744. Epub 2022 Mar 25.
7
Effect of an Antiracism Intervention on Racial Disparities in Time to Lung Cancer Surgery.抗种族主义干预对肺癌手术时间种族差异的影响。
J Clin Oncol. 2022 Jun 1;40(16):1755-1762. doi: 10.1200/JCO.21.01745. Epub 2022 Feb 14.
8
Diagnosis-to-surgery interval and survival for different histologies of stage I-IIA lung cancer.I-IIA期肺癌不同组织学类型的诊断至手术间隔时间与生存率
Transl Lung Cancer Res. 2021 Jul;10(7):3043-3058. doi: 10.21037/tlcr-21-168.
9
Racial Disparity and Social Determinants in Receiving Timely Surgery Among Stage I-IIIA Non-small Cell Lung Cancer Patients in a U.S. Southern State.美国南部一州 I 期-IIIA 期非小细胞肺癌患者及时接受手术的种族差异和社会决定因素。
Front Public Health. 2021 Jun 2;9:662876. doi: 10.3389/fpubh.2021.662876. eCollection 2021.
10
Has COVID-19 Affected Cancer Screening Programs? A Systematic Review.新型冠状病毒肺炎是否影响了癌症筛查项目?一项系统评价。
Front Oncol. 2021 May 17;11:675038. doi: 10.3389/fonc.2021.675038. eCollection 2021.